Novartis AG ADR (NVS)vsScinai Immunotherapeutics Ltd (SCNI)
NVS
Novartis AG ADR
$148.38
-0.99%
HEALTHCARE · Cap: $273.77B
SCNI
Scinai Immunotherapeutics Ltd
$0.41
-6.08%
HEALTHCARE · Cap: $1.47M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 4315537% more annual revenue ($56.58B vs $1.31M). NVS leads profitability with a 23.9% profit margin vs 0.0%. SCNI earns a higher WallStSmart Score of 51/100 (C-).
NVS
Hold49
out of 100
Grade: D+
SCNI
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Intrinsic value data unavailable for SCNI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Revenue surging 30.6% year-over-year
Earnings expanding 87.2% YoY
Conservative balance sheet, low leverage
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
ROE of -102.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : SCNI
The strongest argument for SCNI centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 30.6% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : SCNI
The primary concerns for SCNI are Market Cap, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
NVS profiles as a declining stock while SCNI is a hypergrowth play — different risk/reward profiles.
SCNI carries more volatility with a beta of 2.05 — expect wider price swings.
SCNI is growing revenue faster at 30.6% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
SCNI scores higher overall (51/100 vs 49/100) and 30.6% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Scinai Immunotherapeutics Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Scinai Immunotherapeutics Ltd is a cutting-edge biotechnology company specializing in the development of innovative immunotherapy solutions aimed at treating cancer and autoimmune disorders. Utilizing its proprietary immune modulation platform, Scinai is advancing a robust clinical pipeline that focuses on delivering transformative therapies to improve patient outcomes. With a highly experienced leadership team and a commitment to rigorous research, the company is well-positioned to capitalize on the growing demand for advanced immunotherapeutics in the global healthcare landscape. Strategic partnerships further enhance Scinai's potential for significant growth, establishing it as a key player in the biopharmaceutical sector.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?